Rimonbant shows promise in addressing multiple risk factors

reduced plasma insulin levels and the changed size of LDL particles, we now may have a drug that targets the most frequent cause of clustering risk factors."


A multi-center, double-blind, placebo-controlled study, RIO-Lipids enrolled 1,036 obese patients with dyslipidemia and a BMI between 27 and 40 kg/m2. Patients were randomized into three treatment groups receiving either a daily, fixed dose of 5mg or 20mg of rimonabant or placebo along with a reduced calorie diet for one year.

Patients treated for one year with rimonabant 20mg lost almost 20 lbs (8.6 kg) vs. a loss of only 5 lbs (2.4 kg) on placebo (p<0.001). Nearly three-fourths (72.9%) of these patients treated for a year with rimonabant 20mg lost more than 5% of their body weight vs. placebo (p<0.001) while nearly half (44.3%) lost in excess of 10% of their body weight vs. placebo (p<0.001). While weight loss was the primary endpoint, a waist circumference reduction of 3.4 inches (9.1 cm) in patients completing a year of treatment on rimonabant 20 mg was statistically significant (p<0.001 vs. placebo).

Researchers also designed the RIO-Lipids study to determine if rimonabant, in a group of overweight/obese patients at risk for cardiovascular disease, could improve important factors such as lipid profile, glucose metabolism and other features of the metabolic syndrome. Results show that both the 5 mg and 20 mg doses of rimonabant significantly improved two important indicators of cardiovascular risk, HDL-cholesterol and triglycerides vs. placebo. The patients treated for a year in the 20 mg group achieved an average 23% increase (p<0. 001 vs. placebo) in HDL-cholesterol and a reduction of 15% in triglycerides (p<9x10-5 vs. placebo).

No difference in LDL-cholesterol was observed between rimonabant and placebo. However, rimonabant 20mg delivered positive changes in LDL particle size, a known indicator of atherogenic risk. In patient

Contact: Glenn Lehrman

Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:

(Date:11/19/2015)... Nov. 19, 2015  Although some 350 companies are ... by a few companies, according to Kalorama Information. These include ... of the market share of the 6.1 billion-dollar molecular ... World Market for Molecular Diagnostic s .    ... is still controlled by one company and only a ...
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
Breaking Biology Technology:
Cached News: